For Q4, the one analyst on BioSyent is expecting $3.6M in revenue and earnings of $0.05/share. A side note is that this analyst is not covering Biosyent anymore as his whole department was laid off.
I think that is a reasonable guess as a starting point. Pharma sales in Q3 were $4.068M but included a large order of $627K which will not repeat. Insecticide Sales in Q4 is generally around $40-50K. So, $3.6M shows a slight bit of growth ignoring that large order.
That is short term.
Longer term I expect growth for many years. They should grow 20-25% each year. However, they also have a large cash pile. When the right deal comes, I suspect they will deploy that cash and it will cause a large bump in revenue and earnings for that year.
There was recently a nice conference call with BioSyent on MicroCapClub that gave insight into the longer term strategy.
I expect BioSyent to be a multi-bagger over several years.
